Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gabitril Potential In Anxiety Aided By Positive Side Effect Profile – Cephalon

Executive Summary

Cephalon hopes to market the anti-epileptic Gabitril (tiagabine) for generalized anxiety disorder by 2006 based on a favorable side effect profile

You may also be interested in...



Cephalon Marketing Under Investigation By Philadelphia U.S. Attorney

The Philadelphia U.S. Attorney's investigation into Cephalon's marketing practices covers the entire commercial life of Provigil

Cephalon Marketing Under Investigation By Philadelphia U.S. Attorney

The Philadelphia U.S. Attorney's investigation into Cephalon's marketing practices covers the entire commercial life of Provigil

Cephalon Provigil Has 28% Awareness Among Primary Care Physicians

Cephalon will step up its efforts to target primary care physicians in an effort to raise awareness about the sleep disorder agent Provigil (modafinil)

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043764

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel